Collectively, though EGFR-TKIs demonstrate promising therapeutic effects, considering drug-resistant mutations and activation of alternative signaling pathways, combination therapies are greatly necessary to provides resolutions for drug resistance and new insights into the treatment of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.